Thursday, November 09, 2023
Alimentiv Inc., AcelaBio Inc., and PharmaNest Inc. have recently announced a collaborative effort to advance precision medicine and artificial intelligence (AI)-powered digital pathology solutions for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). This collaboration is particularly significant as there are currently no approved treatments for MASH, making it a crucial area of focus. The partnership brings together Alimentiv's expertise in endpoint assessments and precision medicine analysis, AcelaBio's capabilities as a CAP/CLIA-certified clinical research laboratory, and PharmaNest's proficiency in digital MASH pathology and AI analysis.
AcelaBio, known for its comprehensive digital pathology workflows, will be responsible for analyzing tissue samples to generate full slide images and molecular data. Dr. Niels Vande Casteele, President of AcelaBio, highlights the potential for significant advancements in MASH research through the seamless integration of digital pathology biomarker data and improved clinical development workflows.
Aligned with the collaborative vision, Alimentiv is committed to scientific excellence and innovative designs for early clinical trials. Dr. Wendy Teft, VP of Precision Medicine at Alimentiv, emphasizes the integration of technologies to provide clinical trial sponsors with tools for enhanced histological endpoints, biomarker discovery, and shortened drug development times.
PharmaNest's role in the collaboration involves providing high-resolution quantitative image analysis and AI-powered biomarkers through its digital pathology platform, FibroNest. Dr. Mathieu Petitjean, CEO of PharmaNest, notes the platform's ability to offer continuous assessments, predict liver-related events, and potentially serve as a surrogate endpoint in MASH trials.
Together, these companies aim to revolutionize MASH clinical trials by improving the quality of histologic endpoints, uncovering new biomarkers, and expediting the development of personalized therapies. The collaboration represents a significant step forward in integrating precision medicine and digital pathology solutions, ultimately enhancing the efficiency of early drug development and delivering safe and effective therapies to patients more rapidly. Clinical trial sponsors interested in benefiting from this collaboration are encouraged to reach out to the respective companies for further information.